FOLH1 and prostate carcinoma: Promising preliminary results have been described in the evaluation of PSMA-expressing prostate cancer [20], but also in breast cancer [17], head and neck cancer [18], pancreatic adenocarcinoma [19] and neuroendocrine tumors [20].